Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 8:15 am Pacific Time.
Related news for (LYEL)
- Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
- Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
- MoBot’s Stock Market Highlights – 06/04/25 04:00 PM
- MoBot alert highlights: NASDAQ: CTKB, NASDAQ: LYEL, NYSE: NCL, NYSE: BURU, NASDAQ: MFI (06/04/25 03:00 PM)
- Breaking News: MoBot’s Latest Update as of 06/04/25 02:00 PM